慢性炎症疾病中的IL-23抑制
Vipul Jairath1, Maria Laura Acosta Felquer2, Raymond Jaihyun Cho3
1Departments of Medicine, Division of Gastroenterology, Western University, Ontario, ON, Canada.
Lancet (London, England)
|October 26, 2024
概括
干白素 (IL-23) 抑制剂可有效治疗长期炎症性疾病,如牛皮和炎症性肠病. 与其他治疗方法相比,针对IL-23p19的疗效和安全性更高.
科学领域:
- 免疫学
- 药理学
- 皮肤病学
背景情况:
- 在慢性炎症疾病中,单克隆抗体向细胞因子信号传递.
- 干白素 (IL-23) 抑制剂对于治疗牛皮病和炎症性肠病至关重要.
- 这些抑制剂解决了共同的病理机制,提供了高效和持久的反应.
研究的目的:
- 审查IL-23抑制剂的疗效和安全性.
- 为了比较针对p40和p19子单元的IL-23抑制剂.
- 评估抗体亲和度在IL-23抑制剂疗效中的作用.
主要方法:
- 对IL-23抑制剂的综合临床试验数据的分析.
- 在IL-23抑制剂和瘤死因α抑制剂之间的疗效比较.
- 对积累的长期安全数据进行审查.
主要成果:
- IL-23 抑制剂具有很高的疗效,超过70% 的牛皮患者和高达 50% 的肠道炎症患者出现改善.
- 针对IL-23独特的p19蛋白的抑制剂在斑块性牛皮的治疗中比TNFα抑制剂更有效.
- IL-23 抑制剂的严重不良事件和感染率与安慰剂相当.
结论:
- 在治疗牛皮和炎症性肠道疾病方面,IL-23抑制剂,特别是p19抑制剂是显著的进步.
- 疗效可能因抗体亲和性而受到调节,因此需要进一步研究.
- 这些疗法在已批准的适应症中具有良好的安全性.
相关概念视频
T Cell Types and Functions
955
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
955
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
Inflammatory Response
1.9K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.9K
Drugs Used in Lower Respiratory Disorders: Overview
353
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
353


